Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Lupin Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

13 Mar 2025

925.00

0.70%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication of notice of loss of share certificate of the Company

pdf

Lupin Ltd.

13 Mar 2025

2119.05

0.21%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Mankind Pharma Ltd.

12 Mar 2025

2370.25

-1.86%

Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication

NDTV Profit

The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.

Mankind Pharma Ltd. has an average target of 2901.00 from 2 brokers.

Zydus Lifesciences Ltd.

12 Mar 2025

925.00

0.70%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease.

pdf

Alkem Laboratories Ltd.

12 Mar 2025

5048.25

1.39%

Key diabetes drug price crashes up to 90% as generic versions launched

Business Standard

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Alkem Laboratories Ltd. is trading below its 100 day SMA of 5236.2

Dr. Reddy's Laboratories Ltd.

12 Mar 2025

1210.00

0.82%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Schedule of Analyst/Institutional meet

pdf

Aurobindo Pharma Ltd.

12 Mar 2025

1209.90

0.80%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Plant visit by investor group on March 19, 2025

pdf

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1493.20

-1.42%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Glenmark Pharmaceuticals Ltd. is trading below its 100 day SMA of 1502.0

Zydus Lifesciences Ltd.

12 Mar 2025

925.00

0.70%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus receives final approval from USFDA for Methenamine Hippurate Tablets USP, 1 gram.

pdf

Alkem Laboratories Ltd.

12 Mar 2025

5048.25

1.39%

Alkem launches low-cost diabetes drug in Indian market

Business Line

The company is introducing several combination therapies including Empanorm L (empagliflozin and linagliptin), Empanorm Duo and Alsita E (empagliflozin and sitagliptin), and Empanorm M (empagliflozin and metformin)

Number of FII/FPI investors increased from 334 to 524 in Dec 2024 qtr.

No results found

Is Nifty Pharma worth buying?

303 Votes:

Buy 79.21%

Sell 11.55%

Hold 9.24%

Nifty Pharma PB	5.3
Nifty Pharma PE	32.9
Nifty Pharma DIV	0.6
Nifty Pharma EPS	657.1